No registrations found.
ID
Source
Brief title
Health condition
Sarcopenia, muscle mass, protein, Neuromuscular electrostimulation
Sponsors and support
Maastricht University
Department of Human Movement Sciences
Intervention
Outcome measures
Primary outcome
Primary parameter of this study will be overnight incorporation of stable isotope amino acids from the intrinsically labeled drink.
Secondary outcome
Secondary parameter of this study will be plasma amino acid enrichment after ingestion of the intrinsically labeled protein.
Background summary
Rationale:
With human aging there is a gradual but progressive decline in skeletal muscle mass, termed sarcopenia. While the underlying cause of sarcopenia is likely to be multifaceted, a primary factor is that elderly individuals frequently experience short periods of muscle disuse following limb immobilization or bed-rest (due to injury or illness) causing rapid muscle loss. Feasible strategies for maintaining muscle protein synthesis rates in elderly individuals, and thus having the potential to attenuate the loss of muscle mass during disuse need to be pursued. Local neuromuscular electrical stimulation (NMES) in combination with additional intake of protein offer such a potential strategy but, as yet, remains relatively unexplored.
Objective:
To test the hypothesis that ingesting a nocturnal bolus of protein in combination with NMES stimulates muscle protein synthesis in elderly more than ingesting protein without NMES.
Study design:
Prospective, single blind, intervention study.
Intervention:
Consumption of a 40 g bolus of intrinsically L[1-13C]-phenylalanine labeled casein protein and 70 min of one-legged NMES.
Endpoints:
Enrichments of muscle tissue after ingestion of an [1-13C]-phenylalanine intrinsically labeled casein drink.
Study objective
Is overnight incorporation of [1-13C]-phenylalanine amino acids higher in muscle tissue in combination with NMES than in unstimulated skeletal muscle?
Study design
Overnight (i.e. the morning after ingestion of the stable isotope drink and NMES). Method of measurement is massaspectrometry.
Intervention
Consumption of a 40 g bolus of intrinsically L[1-13C]-phenylalanine labeled casein protein and 70 min of one-legged NMES.
Inclusion criteria
1. Written informed consent;
2. Age ≥ 65 years;
3. Male.
Exclusion criteria
1. Type II diabetes;
2. All co morbidities interacting with mobility and muscle metabolism of the lower limbs (e.g. arthrosis, arthritis, spasticity/rigidity, all neurological disorders, paralysis, hip/knee surgery);
3. Use of anticoagulants, blood diseases, allergy for lidocain;
4. Use of NSAIDs and acetylsalicylic acid;
5. Patients suffering from PKU (Phenylketonuria);
6. Presence of implantable cardioverter defibrillator and/or pacemaker;
7. Performed regular resistance type exercise in the past 6 months;
8. Use of any tools to assist during walking (cane/ crutches/ walker);
9. (Partial) foot/ leg amputation.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL3786 |
| NTR-old | NTR3952 |
| Other | ABR / METC MUMC : 44582 / 13-3-024; |
| ISRCTN | ISRCTN wordt niet meer aangevraagd. |